Qudexy Xr

Migraine, Caloric Restriction, High cholesterol + 16 more

Treatment

20 Active Studies for Qudexy Xr

What is Qudexy Xr

Topiramate

The Generic name of this drug

Treatment Summary

Topiramate is a medication used to control epilepsy and prevent migraine headaches. It was first approved by the FDA in 1996 and later approved for migraine prevention in adults in 2004. It is also used in combination with another drug, phentermine, to help adults lose weight. It has an unusual chemical structure composed of sulfamate and oxygen, which was discovered by chance during the development of an antidiabetic medication.

Topamax

is the brand name

image of different drug pills on a surface

Qudexy Xr Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Topamax

Topiramate

1997

526

Effectiveness

How Qudexy Xr Affects Patients

Topiramate helps to prevent seizures and migraine symptoms by decreasing the activity of neurons in the brain. However, it can also cause metabolic acidosis, changes in mood, suicidal thoughts or attempts, and kidney stones. Taking topiramate with another drug called valproic acid can also lead to hypothermia.

How Qudexy Xr works in the body

Seizures are caused by an electrical disruption in the brain, which causes a temporary disruption of normal brain activity. Topiramate is used to treat these seizures and migraines, although the exact way it works is not fully understood. It likely works by blocking sodium channels in the brain and increasing activity of inhibitory GABA-A receptors while reducing activity of stimulating glutamate receptors. This decreases the electrical signals in the brain, preventing seizures and migraines. Topiramate also blocks some carbonic anhydrase isozymes, but it is unclear what impact this has.

When to interrupt dosage

The recommended dosage of Qudexy Xr is contingent upon the diagnosed condition, including Seizures, Weight Reduction and Tonic - clonic seizures. The quantity of dosage fluctuates as per the procedure of delivery (e.g. Tablet, coated or Tablet) specified in the table underneath.

Condition

Dosage

Administration

Alcoholism

, 25.0 mg, 100.0 mg, 200.0 mg, 50.0 mg, 150.0 mg, 15.0 mg, 23.0 mg, 46.0 mg, 69.0 mg, 92.0 mg, 25.0 meq, 25.0 mg/mL

, Tablet, Oral, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Capsule, coated pellets - Oral, Capsule, coated pellets, Capsule, extended release - Oral, Capsule, extended release, Capsule, Capsule - Oral, Tablet, coated - Oral, Tablet, coated, Solution - Oral, Solution

Obesity

, 25.0 mg, 100.0 mg, 200.0 mg, 50.0 mg, 150.0 mg, 15.0 mg, 23.0 mg, 46.0 mg, 69.0 mg, 92.0 mg, 25.0 meq, 25.0 mg/mL

, Tablet, Oral, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Capsule, coated pellets - Oral, Capsule, coated pellets, Capsule, extended release - Oral, Capsule, extended release, Capsule, Capsule - Oral, Tablet, coated - Oral, Tablet, coated, Solution - Oral, Solution

Exercise

, 25.0 mg, 100.0 mg, 200.0 mg, 50.0 mg, 150.0 mg, 15.0 mg, 23.0 mg, 46.0 mg, 69.0 mg, 92.0 mg, 25.0 meq, 25.0 mg/mL

, Tablet, Oral, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Capsule, coated pellets - Oral, Capsule, coated pellets, Capsule, extended release - Oral, Capsule, extended release, Capsule, Capsule - Oral, Tablet, coated - Oral, Tablet, coated, Solution - Oral, Solution

Lennox Gastaut Syndrome

, 25.0 mg, 100.0 mg, 200.0 mg, 50.0 mg, 150.0 mg, 15.0 mg, 23.0 mg, 46.0 mg, 69.0 mg, 92.0 mg, 25.0 meq, 25.0 mg/mL

, Tablet, Oral, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Capsule, coated pellets - Oral, Capsule, coated pellets, Capsule, extended release - Oral, Capsule, extended release, Capsule, Capsule - Oral, Tablet, coated - Oral, Tablet, coated, Solution - Oral, Solution

Migraine

, 25.0 mg, 100.0 mg, 200.0 mg, 50.0 mg, 150.0 mg, 15.0 mg, 23.0 mg, 46.0 mg, 69.0 mg, 92.0 mg, 25.0 meq, 25.0 mg/mL

, Tablet, Oral, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Capsule, coated pellets - Oral, Capsule, coated pellets, Capsule, extended release - Oral, Capsule, extended release, Capsule, Capsule - Oral, Tablet, coated - Oral, Tablet, coated, Solution - Oral, Solution

Caloric Restriction

, 25.0 mg, 100.0 mg, 200.0 mg, 50.0 mg, 150.0 mg, 15.0 mg, 23.0 mg, 46.0 mg, 69.0 mg, 92.0 mg, 25.0 meq, 25.0 mg/mL

, Tablet, Oral, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Capsule, coated pellets - Oral, Capsule, coated pellets, Capsule, extended release - Oral, Capsule, extended release, Capsule, Capsule - Oral, Tablet, coated - Oral, Tablet, coated, Solution - Oral, Solution

High cholesterol

, 25.0 mg, 100.0 mg, 200.0 mg, 50.0 mg, 150.0 mg, 15.0 mg, 23.0 mg, 46.0 mg, 69.0 mg, 92.0 mg, 25.0 meq, 25.0 mg/mL

, Tablet, Oral, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Capsule, coated pellets - Oral, Capsule, coated pellets, Capsule, extended release - Oral, Capsule, extended release, Capsule, Capsule - Oral, Tablet, coated - Oral, Tablet, coated, Solution - Oral, Solution

Obesity

, 25.0 mg, 100.0 mg, 200.0 mg, 50.0 mg, 150.0 mg, 15.0 mg, 23.0 mg, 46.0 mg, 69.0 mg, 92.0 mg, 25.0 meq, 25.0 mg/mL

, Tablet, Oral, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Capsule, coated pellets - Oral, Capsule, coated pellets, Capsule, extended release - Oral, Capsule, extended release, Capsule, Capsule - Oral, Tablet, coated - Oral, Tablet, coated, Solution - Oral, Solution

at least one weight-related comorbid condition

, 25.0 mg, 100.0 mg, 200.0 mg, 50.0 mg, 150.0 mg, 15.0 mg, 23.0 mg, 46.0 mg, 69.0 mg, 92.0 mg, 25.0 meq, 25.0 mg/mL

, Tablet, Oral, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Capsule, coated pellets - Oral, Capsule, coated pellets, Capsule, extended release - Oral, Capsule, extended release, Capsule, Capsule - Oral, Tablet, coated - Oral, Tablet, coated, Solution - Oral, Solution

Migraine Disorders

, 25.0 mg, 100.0 mg, 200.0 mg, 50.0 mg, 150.0 mg, 15.0 mg, 23.0 mg, 46.0 mg, 69.0 mg, 92.0 mg, 25.0 meq, 25.0 mg/mL

, Tablet, Oral, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Capsule, coated pellets - Oral, Capsule, coated pellets, Capsule, extended release - Oral, Capsule, extended release, Capsule, Capsule - Oral, Tablet, coated - Oral, Tablet, coated, Solution - Oral, Solution

Obesity

, 25.0 mg, 100.0 mg, 200.0 mg, 50.0 mg, 150.0 mg, 15.0 mg, 23.0 mg, 46.0 mg, 69.0 mg, 92.0 mg, 25.0 meq, 25.0 mg/mL

, Tablet, Oral, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Capsule, coated pellets - Oral, Capsule, coated pellets, Capsule, extended release - Oral, Capsule, extended release, Capsule, Capsule - Oral, Tablet, coated - Oral, Tablet, coated, Solution - Oral, Solution

Seizures

, 25.0 mg, 100.0 mg, 200.0 mg, 50.0 mg, 150.0 mg, 15.0 mg, 23.0 mg, 46.0 mg, 69.0 mg, 92.0 mg, 25.0 meq, 25.0 mg/mL

, Tablet, Oral, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Capsule, coated pellets - Oral, Capsule, coated pellets, Capsule, extended release - Oral, Capsule, extended release, Capsule, Capsule - Oral, Tablet, coated - Oral, Tablet, coated, Solution - Oral, Solution

Type 2 Diabetes

, 25.0 mg, 100.0 mg, 200.0 mg, 50.0 mg, 150.0 mg, 15.0 mg, 23.0 mg, 46.0 mg, 69.0 mg, 92.0 mg, 25.0 meq, 25.0 mg/mL

, Tablet, Oral, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Capsule, coated pellets - Oral, Capsule, coated pellets, Capsule, extended release - Oral, Capsule, extended release, Capsule, Capsule - Oral, Tablet, coated - Oral, Tablet, coated, Solution - Oral, Solution

Hypertensive disease

, 25.0 mg, 100.0 mg, 200.0 mg, 50.0 mg, 150.0 mg, 15.0 mg, 23.0 mg, 46.0 mg, 69.0 mg, 92.0 mg, 25.0 meq, 25.0 mg/mL

, Tablet, Oral, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Capsule, coated pellets - Oral, Capsule, coated pellets, Capsule, extended release - Oral, Capsule, extended release, Capsule, Capsule - Oral, Tablet, coated - Oral, Tablet, coated, Solution - Oral, Solution

Epilepsy

, 25.0 mg, 100.0 mg, 200.0 mg, 50.0 mg, 150.0 mg, 15.0 mg, 23.0 mg, 46.0 mg, 69.0 mg, 92.0 mg, 25.0 meq, 25.0 mg/mL

, Tablet, Oral, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Capsule, coated pellets - Oral, Capsule, coated pellets, Capsule, extended release - Oral, Capsule, extended release, Capsule, Capsule - Oral, Tablet, coated - Oral, Tablet, coated, Solution - Oral, Solution

Weight Loss

, 25.0 mg, 100.0 mg, 200.0 mg, 50.0 mg, 150.0 mg, 15.0 mg, 23.0 mg, 46.0 mg, 69.0 mg, 92.0 mg, 25.0 meq, 25.0 mg/mL

, Tablet, Oral, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Capsule, coated pellets - Oral, Capsule, coated pellets, Capsule, extended release - Oral, Capsule, extended release, Capsule, Capsule - Oral, Tablet, coated - Oral, Tablet, coated, Solution - Oral, Solution

increase in physical activity

, 25.0 mg, 100.0 mg, 200.0 mg, 50.0 mg, 150.0 mg, 15.0 mg, 23.0 mg, 46.0 mg, 69.0 mg, 92.0 mg, 25.0 meq, 25.0 mg/mL

, Tablet, Oral, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Capsule, coated pellets - Oral, Capsule, coated pellets, Capsule, extended release - Oral, Capsule, extended release, Capsule, Capsule - Oral, Tablet, coated - Oral, Tablet, coated, Solution - Oral, Solution

Mood Disorders

, 25.0 mg, 100.0 mg, 200.0 mg, 50.0 mg, 150.0 mg, 15.0 mg, 23.0 mg, 46.0 mg, 69.0 mg, 92.0 mg, 25.0 meq, 25.0 mg/mL

, Tablet, Oral, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Capsule, coated pellets - Oral, Capsule, coated pellets, Capsule, extended release - Oral, Capsule, extended release, Capsule, Capsule - Oral, Tablet, coated - Oral, Tablet, coated, Solution - Oral, Solution

Chronic Weight Management therapy

, 25.0 mg, 100.0 mg, 200.0 mg, 50.0 mg, 150.0 mg, 15.0 mg, 23.0 mg, 46.0 mg, 69.0 mg, 92.0 mg, 25.0 meq, 25.0 mg/mL

, Tablet, Oral, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Capsule, coated pellets - Oral, Capsule, coated pellets, Capsule, extended release - Oral, Capsule, extended release, Capsule, Capsule - Oral, Tablet, coated - Oral, Tablet, coated, Solution - Oral, Solution

Warnings

Qudexy Xr Contraindications

Condition

Risk Level

Notes

Acidosis

Do Not Combine

There are 20 known major drug interactions with Qudexy Xr.

Common Qudexy Xr Drug Interactions

Drug Name

Risk Level

Description

Abemaciclib

Major

The metabolism of Abemaciclib can be increased when combined with Topiramate.

Acalabrutinib

Major

The metabolism of Acalabrutinib can be increased when combined with Topiramate.

Acenocoumarol

Major

The metabolism of Acenocoumarol can be increased when combined with Topiramate.

Alectinib

Major

The metabolism of Alectinib can be increased when combined with Topiramate.

Alpelisib

Major

The metabolism of Alpelisib can be increased when combined with Topiramate.

Qudexy Xr Toxicity & Overdose Risk

The toxic dose of topiramate in rats is above 1500 mg/kg. People who overdose on topiramate may experience symptoms such as low blood pressure, extreme acidity in the body, coma, stomach pain, vision problems, seizures, drowsiness, trouble speaking, confusion, dizziness, agitation, and depression. If the overdose is recent, doctors may suggest vomiting or pumping the stomach, as well as providing supportive care with activated charcoal and hemodialysis.

Qudexy Xr Novel Uses: Which Conditions Have a Clinical Trial Featuring Qudexy Xr?

313 active clinical trials are currently being conducted to assess the potential of Qudexy Xr to ameliorate Type 2 Diabetes, Migraine and Exercise-related issues.

Condition

Clinical Trials

Trial Phases

Exercise

58 Actively Recruiting

Not Applicable, Phase 2, Phase 3

Weight Loss

0 Actively Recruiting

Mood Disorders

0 Actively Recruiting

Migraine

51 Actively Recruiting

Phase 4, Not Applicable, Phase 1, Phase 3, Phase 2, Early Phase 1

Obesity

0 Actively Recruiting

Chronic Weight Management therapy

0 Actively Recruiting

Migraine Disorders

1 Actively Recruiting

Phase 3

Hypertensive disease

27 Actively Recruiting

Not Applicable, Phase 1, Phase 2, Phase 3

Seizures

5 Actively Recruiting

Phase 3, Phase 2, Phase 1

High cholesterol

0 Actively Recruiting

Obesity

0 Actively Recruiting

at least one weight-related comorbid condition

0 Actively Recruiting

Lennox Gastaut Syndrome

2 Actively Recruiting

Phase 1, Phase 2, Phase 4

Obesity

0 Actively Recruiting

Caloric Restriction

0 Actively Recruiting

Epilepsy

0 Actively Recruiting

Alcoholism

7 Actively Recruiting

Not Applicable, Phase 2, Phase 3

Type 2 Diabetes

162 Actively Recruiting

Not Applicable, Phase 1, Phase 2, Phase 3, Phase 4, Early Phase 1

increase in physical activity

0 Actively Recruiting

Qudexy Xr Reviews: What are patients saying about Qudexy Xr?

5

Patient Review

9/11/2017

Qudexy Xr for Migraine Prevention

I use this because I have basilar migraines and i was on 100 mg of topomax xr but it stopped working for me so my neurologist bumped me up to 150mg to quedexy and it works great for me i have had no probelms! when i was taking the topomax I had tingling in my fingers and toes and knees and I also had nightmares for a month everytime I closed my eyes, but with quedexy I have never felt better!

2.7

Patient Review

10/17/2016

Qudexy Xr for Migraine Prevention

I was previously taking topamax 100mg, but my doctor switched me to Qudexy at my annual visit. I found that I wasn't in a fog anymore, which was great! However, I experienced terrible stomach issues and bad tingling in my arms and legs. I tried staying with the medication for 3 weeks, but the stomach problems were too much to handle. I'm currently trying Trokendi to see if it will be more effective.

2

Patient Review

1/14/2021

Qudexy Xr for Migraine Prevention

Although this medication did help to lessen my migraines by half, the hair loss after just three months was not worth it. Additionally, I frequently felt tingling in my fingers and toes while taking this drug.

1.7

Patient Review

7/15/2016

Qudexy Xr for Migraine Prevention

I experienced a lot of negative side effects, like nausea and suicidal thoughts. This medication was ineffective for me, so I do not recommend it to others who are looking for relief from migraines.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about qudexy xr

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What are the side effects of Qudexy XR?

"The following effects may occur: fatigue, drowsiness, dizziness, loss of coordination, tingling in the extremities, loss of appetite, changes in food taste, diarrhea, and weight loss."

Answered by AI

What is Qudexy XR used for?

"Qudexy XR is a prescription medicine that can be used to prevent migraine headaches in adults and adolescents 12 years and older, and to treat certain types of seizures (partial-onset seizures and primary generalized tonic-clonic seizures) in adults and children 2 years and older."

Answered by AI

Is Qudexy the same as topiramate?

"The active ingredient in both Topiramate Extended-Release Capsules and Qudexy® XR is topiramate. Topiramate Extended-Release Capsules are manufactured by Upsher-Smith, while Qudexy® XR is manufactured by UCB, Inc."

Answered by AI

Is Qudexy XR used for weight loss?

"No, you should not use Qudexy XR for weight loss. Although weight loss is a potential side effect of the medication, the main purpose of Qudexy XR is to help people with epilepsy or those who suffer from migraines."

Answered by AI

Clinical Trials for Qudexy Xr

Image of Faculty of Health Sciences in Winnipeg, Canada.

Saskatoon Berries for Type 2 Diabetes

18 - 74
All Sexes
Winnipeg, Canada

Diabetes becomes epidemic in worldwide countries. Diabetes Canada indicated that 30% of adults in Manitoba are diabetes or prediabetes. Nine out of ten diabetic patients are type 2 diabetes (T2D). T2D is characterized by insulin resistance and obesity. Uncontrolled diabetes leads to serious consequences including heart attack, stroke, chronic renal failure, liver failure, blindness and low limb amputation. Most of hypoglycemic medications have certain side effects. Natural foods or nutraceuticals with hypoglycemic potential are expected to provide a safer management for diabetic patients. Saskatoon berry is a popular fruit in Canadian Prairie and Northern states in USA. Our previous studies demonstrated Saskatoon berry (SB) powder attenuated hyperglycemia, hyperlipidemia, insulin resistance, inflammation, liver steatosis and gut dysbiosis in diet-induced insulin resistant mice, a model for T2D. The findings of the glucose and lipid lowering or liver protective effects of SB powder have been supported by another group in Australia in high fat fed rats. Our preliminary studies in 20 healthy subjects demonstrated that dried whole SB (40 g/day for 10 weeks) significantly reduced fasting plasma glucose, total and LDL-cholesterol, systolic blood pressure, and increased plasma glucagon-like peptide compared to baseline, which was associated with increased intake of total fiber and decreased intake of saturated fat. The changes in metabolic and vascular variables significantly correlated with the alterations in gut microbiota The combination of findings suggest that SB is good candidate of prebiotic functional food as a supplemental remedy for reducing the risk for metabolic syndrome and preventing or managing T2D. The effect of Saskatoon berry and its products on metabolic disorders have not been studied in diabetic subjects. We propose to examine the effects of oral administration of freeze-dried whole SB on glucose metabolism, insulin resistance and gut microbiota in untreated prediabetes and new type 2 diabetic patients compared to a control dried fruit in a randomized controlled trial.

Waitlist Available
Dietary Supplement

Faculty of Health Sciences

Image of Arkansas Children's Research Institute in Little Rock, United States.

We Move with Windy for Motor Skills

Any Age
All Sexes
Little Rock, AR

The long-term goal of this project is to learn whether a tailored physical activity program is practical, enjoyable, and helpful for families, and whether it has the potential to improve children's physical development and health. Before launching a large study, the research team completed several early phases to make sure the program met families' needs. First, a needs assessment was conducted with mothers to understand barriers to physical activity and what types of support would be most useful. Using this feedback, the program was refined and tested with three mother-child pairs over six weeks. Finally, there was an 18-week pilot randomized trial to examine feasibility and acceptability. Researchers are now conducting a larger randomized trial with up to 266 families. Half of the families are randomly assigned to receive the physical activity program, and half to a comparison group. The program combines fun, age-appropriate movement activities for children with practical support for parents. Sessions focus on building core movement skills such as jumping, balancing, running, and throwing, while also encouraging confidence, coordination, and enjoyment of being active. Activities can be adapted to each child's ability and home environment, making the program realistic for busy families. The program includes both in-person sessions and technology-based activities. In-person sessions provide hands-on support for learning new skills. Technology-based activities offer simple ideas families can use at home or during daily routines, such as hopping games, balance challenges, or quick movement breaks. Because parents in earlier phases wanted nutrition support, in-person sessions also includes a brief, child-friendly exposure to fruits and vegetables, along with simple recipes. A "Tasting Party" at the start of the program allows children to try different foods, and Veggie Meter scans at the beginning and end of the study help track changes in fruit and vegetable intake. Overall, this study will help determine whether a family-tailored physical activity program is a promising approach to improving physical activity, movement skills, and early health indicators in young children born to mothers with obesity.

Recruiting
Has No Placebo

Arkansas Children's Research Institute

Taren Swindle

Image of Arkansas Children's Research Institute in Little Rock, United States.

Exercise Program for Pregnant Women

18+
Female
Little Rock, AR

Regular physical activity during pregnancy is safe and offers many health benefits for both mothers and their babies. Research over the past decade shows that exercise can help pregnant women gain a healthy amount of weight, lower their risk of gestational diabetes and high blood pressure, and reduce stress, anxiety, and symptoms of postpartum depression. Babies also benefit when their mothers are active, with lower risks of preterm birth, unhealthy birth size, and childhood obesity. Despite this strong evidence, very few exercise programs for pregnant women have been tested in real-world community settings, such as fitness centers, community health programs, or local organizations. Even fewer studies explain how these programs were delivered or what helped them succeed. Without this information, it is difficult for communities and health programs to offer exercise support that is both effective and practical for pregnant women. To address this gap, the research team adapted an evidence-based program called EXPECTING so it could be delivered by community organizations. Previous participants and community advisors helped to understand what changes were needed to make the program easier to offer while still keeping it safe and effective. The core parts of the program, including the type, amount, and intensity of aerobic and strength-building exercises, remained the same and are based on established pregnancy exercise guidelines. The adapted program, called COMMUNITY EXPECTING, includes both aerobic exercise and resistance training. The research team also developed specific supports to help community instructors deliver the program consistently and with confidence. All program components have already been tested in community settings and shown to be realistic, acceptable, and delivered as planned. This study will examine whether offering a structured exercise program in community settings helps pregnant women be more physically active than usual prenatal care alone. We will also assess whether the program can be delivered successfully and in a way that works for both participants and community providers. The results will help determine whether COMMUNITY EXPECTING is a practical approach for supporting healthy pregnancies in real-world settings.

Recruiting
Has No Placebo

Arkansas Children's Research Institute

Taren Swindle

Have you considered Qudexy Xr clinical trials?

We made a collection of clinical trials featuring Qudexy Xr, we think they might fit your search criteria.
Go to Trials
Image of Miles Square Health Center Chicago in Chicago, United States.

Food is Medicine for High Blood Pressure and Obesity

Any Age
All Sexes
Chicago, IL

The goal of this clinical trial is to treat both hypertension and obesity in adults using a food is medicine framework. Participants will be randomized 1:1 to FIM+DASH or usual-care control. The 24-week trial includes a 12-week FIM+DASH intervention followed by a 12-week maintenance period and leverages existing partnerships with community-based organizations for home food delivery and culinary skill-skill building. The main questions it aims to answer are: (1) What is the effect of FIM+DASH vs. usual care control on blood pressure? (2) What is the effect of FIM+DASH vs. usual care control on DASH diet adherence (diet quality), body weight, and waist circumference? (3) How to identify factors associated with the sustainability and scalability of FIM+DASH in real-world settings?

Phase 2
Waitlist Available

Miles Square Health Center Chicago (+3 Sites)

Image of Arizona State University in Phoenix, United States.

App-based Breathing Program for Migraine

18+
All Sexes
Phoenix, AZ

Migraine is one of the most common neurological disorders, characterized by recurrent headaches, sensitivity to light and movement, nausea, and autonomic dysregulation. Although mind-body interventions like biofeedback have shown their efficacy, they remain underutilized due to barriers such as transportation, time constraints, lack of awareness, stigma, and cost. A targeted approach to enhancing HRV is HRV biofeedback (HRVB), a technique using visual or auditory feedback to help people regulate HRV through slow-paced breathing and positive emotional regulation to promote ANS balance and emotional resilience. Investigators will conduct a remotely delivered pilot RCT of an 8-week, 10 min/day, novel app-based HRVB intervention compared to a sham control intervention (matching intervention time and attention with no biofeedback component) in adult with chronic migraine. Investigators hypothesize data collected from the study will: a) support the feasibility and acceptability of the remotely delivered app-based HRVB intervention among adults with chronic migraine, and b) provide insights into refining the intervention by examining patterns of change in migraine and psychological outcomes from pre- to post-intervention.

Waitlist Available
Online Trial

Arizona State University

Have you considered Qudexy Xr clinical trials?

We made a collection of clinical trials featuring Qudexy Xr, we think they might fit your search criteria.
Go to Trials
Image of Human Performance Clinical Research Lab in Fort Collins, United States.

Virtual Exercise for Cancer

18+
All Sexes
Fort Collins, CO

The goal of this research study is to look at how live, online group exercise compares to recorded videos for helping increase physical activity levels, improve physical fitness and quality of life, and reduce loneliness among those living with and beyond cancer. The following aims have been established for this study: * Aim 1: Examine the effect of a group-based videoconference physical activity (PA) intervention on moderate to vigorous physical activity \[MVPA\] (i.e., aerobic and resistance exercise). * Aim 2: Examine the effect of the intervention on additional health-related outcomes including physical fitness (i.e., aerobic endurance, muscular strength), and quality of life at both timepoints. * Aim 3: Explore potential mediators and moderators of intervention effects. We will examine mediators (e.g., self-efficacy, outcome expectations, group cohesion) and moderators (e.g., age, cancer stage, neighborhood walkability) of the intervention on MVPA. * Exploratory Aim: Determine whether a group-based videoconference PA intervention reduces loneliness among cancer survivors. Researchers will randomize participants into one of two guided exercise groups that are 12-weeks long in duration. Participants will be asked to complete online fitness assessments and surveys as well as wear a physical activity monitor device and watch a few times throughout the study. The whole study is 9-months long in duration with a 6-month free-living period where no study activities will take place.

Recruiting
Has No Placebo

Human Performance Clinical Research Lab

Heather J Leach, PhD

Image of NYU Langone Health in New York, United States.

Adaptive Dietary Intervention for Type 2 Diabetes

18+
All Sexes
New York, NY

The investigators will examine the feasibility, acceptability, and effect of an adaptive dietary intervention over 24 weeks (12-week intervention, 12-week follow-up) among Asian Americans with Type 2 diabetes. Participants (N=120; 60 Chinese Americans and 60 Vietnamese Americans) will be 2:1 randomized to one of two arms: adaptive dietary intervention or standard of care (SC). The intervention will begin with continued glucose monitoring (CGM) use only during weeks 0-4. At week 4, participants who achieve the glycemic control goal (at least an 8% increase in time in range \[TIR\] from baseline) will continue with the CGM alone during weeks 4-12 ("CGM Alone"); otherwise, culturally and linguistically adapted glucose excursion minimization (GEM) will be augmented with CGM ("CGM-GEM").

Waitlist Available
Has No Placebo

NYU Langone Health

Yaguang Zheng, PhD, RN

Image of KPNC Division of Research in Pleasanton, United States.

MetSense Risk Flag for Type 2 Diabetes

18+
All Sexes
Pleasanton, CA

People with serious mental illness have high risk for type 2 diabetes due to multiple risk factors, including the metabolic side effects of psychotropic medications that are used to treat these conditions. Type 2 diabetes is preventable through lifestyle and pharmacological interventions, but many people with serious mental illness do not receive regular screening for type 2 diabetes risk. In many health care settings, clinical pharmacists are increasingly managing patients with serious mental illness and have expertise in monitoring the metabolic side effects of psychotropic medications. This study evaluates the feasibility and acceptability of using a diabetes prediction model that is based on electronic health record data (the MetSense risk flag) to alert clinical pharmacists about patients who are at high diabetes risk, prompting these clinicians to prioritize diabetes risk management services.

Waitlist Available
Has No Placebo

KPNC Division of Research

Esti Iturralde, PhD

Have you considered Qudexy Xr clinical trials?

We made a collection of clinical trials featuring Qudexy Xr, we think they might fit your search criteria.
Go to Trials